drugs

ANAURAN ® Polymyxin B, Neomycin and Lidocaine

ANAURAN ® is a drug based on Polymyxin B sulfate, Neomycin sulfate and Lidocaine hydrochloride.

THERAPEUTIC GROUP: Antimicrobials.

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications ANAURAN ® Polymyxin B, Neomycin and Lidocaine

ANAURAN® is indicated for the treatment of acute and chronic ear infections.

Mechanism of action ANAURAN ® Polymyxin B, Neomycin and Lidocaine

ANAURAN ® owes its therapeutic activity to its three active ingredients with antibiotic and anesthetic action, effective against ear canal infections.

The solution in ear drops in fact allows the active ingredients to reach the ear canal while significantly reducing the systemic absorption of the drug and thus limiting the onset of potential side effects.

More precisely Polymyxin B, by binding to the cell membranes of Gram negative microorganisms, would determine its cleansing compromising its osmotic integrity, inducing the death of the bacteria while Neomycin, active both against Gram negative and positive bacteria, inhibiting protein synthesis through binding to 16S ribosomal subunits, it would help Polymyxin in its microbicidal activity.

Lidocaine at the same time, acting as a local anesthetic, would guarantee a more effective control of the painful symptoms, classically present in most otological affections.

Studies carried out and clinical efficacy

LIDOCAINE IN THE TREATMENT OF PAIN IN PROGRESS OF OTITIS MEDIA

J Fam Pract. 2008 Jun; 57 (6): 370-3.

Work that demonstrates the effectiveness of Lidocaine or benzocaine in reducing the classic pain associated with acute otitis media in pediatric patients, thus making associated antibiotic therapy easier.

POLYMIXINE B IN THE TREATMENT OF EXTERNAL OTITIS

Auris Nasus Larynx. 2008 Dec; 35 (4): 480-4. doi: 10.1016 / j.anl.2007.09.013. Epub 2008 Mar 7.

A study that demonstrates how Polymyxin B can be effective in the treatment of external otitis, together with gentamicin and ciprofloxacin, is a first choice treatment.

NEOMYCIN IN CLINICAL PRACTICE

Clin Otolaryngol. 2006 Dec; 31 (6): 504-7.

Interesting clinical trial that reveals the efficacy of Neomycin, when added to other active ingredients, in the treatment of otitis externa even when complicated by infections of the mastoid cavities.

Method of use and dosage

ANAURAN ®

Ear drops of 1, 000, 000 IU of Polymyxin B, 0.500 g of Neomycin Sulphate and 4 g of Lidocaine hydrochloride per 100 ml of solution.

Generally it is recommended to instill 4-5 drops for 2-4 times a day in adults or 2-3 drops for 3-4 times a day in children, taking care to keep the head bent on one side for a few minutes.

The treatment, whose duration depends on the therapeutic response obtained, should not be extended in any case more than 10 consecutive days.

Warnings ANAURAN ® Polymyxin B, Neomycin and Lidocaine

The use of ANAURAN ® should in any case be preceded by a careful medical examination in order to assess the patient's clinical conditions and the prescriptive appropriateness.

The presence of neomycin in ANAURAN ® would expose the patient to potential sensorineural damage, especially following prolonged use of the drug.

In the same way, long-term therapies would significantly increase the risk of potential local adverse reactions, furthermore favoring the onset of polypharmacy-resistant microbial strains.

ANAURAN ® contains among its excipients Benzalkonium chloride, an element with irritating power.

PREGNANCY AND BREASTFEEDING

ANAURAN ® is generally contraindicated during pregnancy and in the subsequent period of breastfeeding.

However in cases of real necessity its use could take place under the strict supervision of your gynecologist.

Interactions

At the moment active ingredients whose administration could alter the pharmacodynamic and pharmacokinetic characteristics of ANAURAN ® are not known.

Contraindications ANAURAN ® Polymyxin B, Neomycin and Lidocaine

The use of ANAURAN ® is contraindicated in patients with hypersensitivity to one of its active ingredients or to the relevant excipients and in patients suffering from perforation of the tympanic membrane.

Undesirable effects - Side effects

The use of ANAURAN ® could determine the appearance of dermatitis, itching, irritation and only rarely ototoxicity.

The incidence of these side effects is proportional to the duration of the therapy.

Note

ANAURAN ® is a non-prescription drug